Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
1997 2
1998 2
1999 9
2000 1
2001 5
2002 2
2003 3
2004 8
2005 6
2006 13
2007 12
2008 7
2009 14
2010 12
2011 18
2012 15
2013 11
2014 10
2015 18
2016 16
2017 18
2018 33
2019 26
2020 22
2021 30
2022 23
Text availability
Article attribute
Article type
Publication date

Search Results

306 results
Results by year
Filters applied: . Clear all
Page 1
Polyneuropathies.
Sommer C, Geber C, Young P, Forst R, Birklein F, Schoser B. Sommer C, et al. Among authors: schoser b. Dtsch Arztebl Int. 2018 Feb 9;115(6):83-90. doi: 10.3238/arztebl.2018.083. Dtsch Arztebl Int. 2018. PMID: 29478436 Free PMC article. Review.
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Diaz-Manera J, et al. Among authors: schoser b. Lancet Neurol. 2021 Dec;20(12):1012-1026. doi: 10.1016/S1474-4422(21)00241-6. Lancet Neurol. 2021. PMID: 34800399 Clinical Trial.
A systematic review on the definition of rhabdomyolysis.
Stahl K, Rastelli E, Schoser B. Stahl K, et al. Among authors: schoser b. J Neurol. 2020 Apr;267(4):877-882. doi: 10.1007/s00415-019-09185-4. Epub 2019 Jan 7. J Neurol. 2020. PMID: 30617905
Myotonic Dystrophy Type 2.
Schoser B. Schoser B. 2006 Sep 21 [updated 2020 Mar 19]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. 2006 Sep 21 [updated 2020 Mar 19]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. PMID: 20301639 Free Books & Documents. Review.
Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Laforêt P, Mengel KE, Pestronk A, Pouget J, Schoser B, Straub V, Trivedi J, Van Damme P, Vissing J, Young P, Kacena K, Shafi R, Thurberg BL, Culm-Merdek K, van der Ploeg AT; NEO1 Investigator Group. Pena LDM, et al. Among authors: schoser b. Neuromuscul Disord. 2019 Mar;29(3):167-186. doi: 10.1016/j.nmd.2018.12.004. Epub 2018 Dec 17. Neuromuscul Disord. 2019. PMID: 30770310 Free article. Clinical Trial.
In Reply.
Schoser B, Sommer C, Geber C, Forst R, Young P, Birklein F. Schoser B, et al. Dtsch Arztebl Int. 2018 Apr 27;115(17):297. doi: 10.3238/arztebl.2018.0297. Dtsch Arztebl Int. 2018. PMID: 29789112 Free PMC article. No abstract available.
[Neuromuscular diseases].
Schoser B, Zierz S. Schoser B, et al. Nervenarzt. 2011 Jun;82(6):695-6. doi: 10.1007/s00115-010-3038-0. Nervenarzt. 2011. PMID: 21660611 German. No abstract available.
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, Toscano A, Castelli J, Díaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS; PROPEL Study Group. Schoser B, et al. Lancet Neurol. 2021 Dec;20(12):1027-1037. doi: 10.1016/S1474-4422(21)00331-8. Lancet Neurol. 2021. PMID: 34800400 Clinical Trial.
306 results